Amwill Healthcare Limited is preparing for its initial public offering (IPO), scheduled to open from February 5 to February 7, 2025, with an aim to raise approximately ₹59.98 crores. The IPO will consist of a fresh issue of ₹48.88 crores and an offer for sale of up to 10,00,000 equity shares, priced between ₹105 and ₹111 per share. Established in 2017, Amwill specializes in developing derma-cosmetic products, focusing on dermatological and aesthetic solutions that cater to diverse skin types.
₹00
₹111
--
Expert Opinions
Market sentiment for the Amwill Healthcare IPO is optimistic, driven by increasing consumer interest in dermatological and cosmetic products, particularly as awareness of skincare grows. Company strengths include a strong product portfolio featuring innovative derma-cosmetic solutions and a commitment to high-quality ingredients, positioning Amwill as a trusted brand in the skincare market. Risks and challenges involve potential fluctuations in raw material costs and the competitive landscape, which could affect pricing strategies and profit margins.
Valuation analysis for FY 2024 indicates a return on equity (ROE) of 67.67%, return on capital employed (ROCE) of 83.32%, and return on net worth (RoNW) of 67.67%, reflecting robust profitability and efficient capital utilization. From a long-term investment perspective, Amwill Healthcare is well-positioned to capitalize on the growing demand for skincare products.
Investor Considerations
Investors considering the Amwill Healthcare IPO should evaluate several key factors. Company performance and fundamentals indicate a positive trajectory, with revenues increasing from ₹30.17 crores in FY2023 to ₹35.79 crores in the first nine months of FY2024, alongside a net profit of ₹11 crores, reflecting effective operational management. The sector outlook is promising, driven by rising consumer demand for skincare and derma-cosmetic products.
The IPO valuation reveals a price-to-earnings (P/E) ratio of approximately 55.50, and a profit after tax (PAT) margin of 10.32%, indicating a strong financial position with no debt. Growth prospects remain robust as the company plans to expand its product range and enhance its market presence. However, potential risk factors include competition and fluctuations in raw material prices. A long-term investment horizon is advisable as Amwill aims to capitalize on the growing skincare market for sustained growth and profitability.
| Date | GMP | Trend |
|---|---|---|
| 11 Feb 2025 11.04 | ₹00 | --- |
| 10 Feb 2025 10.36 | ₹00 | --- |
| 09 Feb 2025 12.20 | ₹00 | Down |
| 08 Feb 2025 20.46 | ₹5 | --- |
| 07 Feb 2025 20.05 | ₹5 | --- |
| 06 Feb 2025 19.59 | ₹5 | Down |
| 05 Feb 2025 11.04 | ₹15 | --- |
| 04 Feb 2025 16.14 | ₹15 | Up |
| 03 Feb 2025 11.22 | ₹00 | --- |
FAQs
The Grey Market Premium showed moderate accuracy in predicting Amwill Healthcare’s listing sentiment, though missed the magnitude. While the GMP of ₹0 suggested weak market enthusiasm with a flat listing, the stock actually listed at a significant discount of 19.95%. With a prediction error of 19.95%, the GMP correctly indicated negative market sentiment but failed to capture the full extent of the downside, demonstrating partial reliability as a sentiment indicator in this case.
Amwill Healthcare IPO Current GMP is ₹00.
Amwill Healthcare IPO Expected Returns is 0.00%.
Amwill Healthcare IPO estimated listing price is ₹111.